Omeros will price its recently approved drug for a life-threatening transplant complication in adults and children aged two and older at $36,000 per single-dose vial, CEO Gregory Demopulos said on a call with analysts on Wednesday. ...

SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026. The lawsuit follows a series of regulatory setbacks—including an SEC subpoena and a devastating Complete Response Letter (CRL) from the FDA—that led to a sharp stock decline, with the final news t ...

证券代码：002675 证券简称：东诚药业 公告编号：2026-004 烟台东诚药业集团股份有限公司 登录新浪财经APP 搜索【信披】查看更多考评等级 东诚北方被首次认定为高新技术企业，证书编号：GR202537000854，发证日期：2025年12月8日，有效 期：三年；东诚大洋被重新认定为高新技术企业，证书编号：GR202537001805，发证日期：2025年12 月8日，有效期：三年。 根据《中华人民共和国企业所得税法》等相关规定，东诚北方的首次高新技术企业认定和东诚大洋高新 技术企业的重新认定，使东诚北方和东诚大洋自本次通过高新技术企业认定后连续三年可享受国家关于 高新技术企业的相关优惠政策，即按15%的税率缴纳企业所得税，不会对公司已披露的主要财务数据和 指标产生重大影响。 特此公告。 烟台东诚药业集团股份有限公司董事会 2026年1月8日 关于子公司通过高新技术企业认定与重新认定的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 近日，烟台东诚药业集团股份有限公司（以下简称"公司"）子公司烟台东诚北方制药有限公司（以下简 称"东诚北方"）和烟 ...

SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter (“CRL”) from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing’s syndrome) – relacorilant. The news and severe market reaction has prompted national shareholder rights law firm Hagens Berman to commence an investigation into wh ...

核心观点 - LENZ Therapeutics 在2025年第四季度成功推出其首款产品VIZZ™ (aceclidine ophthalmic solution) 1.44% 用于治疗老花眼 并在上市首季度取得了超出预期的商业表现 包括约160万美元的净产品收入和超过2万张已配药处方 显示出强劲的早期市场接受度 [1][2][7] 产品与市场 - VIZZ™ 是首款且唯一一款获得FDA批准的基于阿西克兰(aceclidine)的滴眼液 用于治疗老花眼 这是一种每日一次、不含防腐剂的单剂量滴眼液 可恢复长达10小时的清晰近视力 [1][5][9] - 老花眼是一种与年龄相关的、不可避免的近视力丧失 全球估计有18亿人、美国有1.28亿人受其影响 通常从45岁左右开始症状变得明显 [5][6][8] 2025年第四季度商业表现 - 产品于2025年10月上市 并在11月中旬通过电子药房和几乎所有零售药店建立了全面的多渠道可及性 [1][7] - 2025年第四季度实现净产品收入约160万美元 [1][7] - 在2025年第四季度 已配药处方超过2万张 超出了公司预期 [1][2][7] - 超过6500名独特的眼科护理专业人士(ECP)开具了VIZZ处方 其中超过55%在第四季度多次开具 表明早期信心和采用度 [1][2][7] 近期公司动态 - 2026年1月 公司与Lunatus就VIZZ在中东地区达成了独家商业化合作 这是VIZZ在美国以外的第四个商业化合作 根据协议 LENZ将获得预付款、监管和商业里程碑付款 以及通过预定的最低产品供应价格获得该地区产生的收入的很大一部分 [4]

CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to provide runway ...

- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026 - - Company to host ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

In this article, we take a look at the 9 Best Performing Micro Cap Stocks in 2025.A Bloomberg report published on January 2, 2026, argues that 2025 was an everything rally. Global stocks, bonds, credit, and commodities all rallied together and delivered the strongest cross‑asset performance since 2009. This also made risk‑taking highly rewarding, said the report. And which is why even companies with the smallest market capitalization, also called micro-caps, saw substantial growth. The Dow Jones US Micro-Ca ...

New York, New York--(Newsfile Corp. - January 7, 2026) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLA ...